Sagimet Biosciences

SGMT · NASDAQ

$9.74+$0.88 (+9.93%)TodayMarket closed · Oct 20, 7:44 PM ET

Prev close $8.86

SGMT analyst rating

BuyConsensus of 9 analysts over the last 12 months. 89% rate it a buy.

Strong buy0
Buy8
Hold0
Underperform0
Sell1

12-month price target · 14 analysts

Average $28.48 (+192.4% upside)

Low: $7.07
Now: $9.74
High: $58.80

Upgrades and downgrades

The latest rating actions, newest first

SGMT analyst upgrades, downgrades and rating actions
Firm	Date	Action	Rating	Price target	Hit rate
HC Wainwright & Co.	Oct 5, 2026	Maintains	Buy	$29.00	36%
Guggenheim	Oct 2, 2026	Maintains	Buy	$25.00 → $26.00	57%
Oppenheimer	Oct 1, 2026	Maintains	Outperform	$33.00 → $38.00	43%
Citizens	Oct 1, 2026	Maintains	Market Outperform	$29.00 → $27.00	47%
Goldman Sachs	Sep 24, 2026	Initiates	Sell	$7.00	42%
Barclays	Sep 9, 2026	Upgrade	Equal-Weight → Overweight	$8.00 → $18.00	45%
Cantor Fitzgerald	Sep 9, 2026	Initiates	Overweight	$10.71	20%
HC Wainwright & Co.	Aug 25, 2026	Maintains	Buy	$29.00	36%
Citizens	Aug 14, 2026	Maintains	Market Outperform	$12.00 → $29.00	47%
Canaccord Genuity	Aug 12, 2026	Maintains	Buy	$49.00 → $56.00	44%

The case for and against

Updated Oct 14, 2026

Bull case

Sagimet Biosciences is supported by a differentiated acne franchise built around denifanstat, where 52-week data showed efficacy improving well beyond the Week-12 endpoint and reaching about 58% IGA success with roughly 73% total-lesion and 78% inflammatory-lesion reductions. The fact that efficacy deepened through around Week 24 and remained durable with a clean long-term safety profile strengthens confidence that the drug can be used chronically, potentially expanding patient months on therapy and supporting a better commercial profile than short-course treatments. This also meaningfully de-risks the upcoming AURORA Phase 3 study, while the company’s ~$366M pro forma cash and runway into 2029 provide funding flexibility for denifanstat and TVB-3567.

Bear case

Sagimet Biosciences is viewed negatively because, despite denifanstat’s improved clinical profile in acne, the company still faces meaningful execution risk around replicating efficacy and safety in a broader population, including adolescents, while long-term tolerability and durability remain unproven. Its valuation depends on a DCF using an 11.3% WACC and a 12.5x exit multiple on 2036 estimates, but that framework is undermined by major downside risks from trial failure, regulatory setbacks, competitive pressure, and uncertainties around TVB-3567 and other pipeline assets. Financially, the company is expected to remain loss-making until commercialization and likely through the early launch phase, with a need for additional capital that could dilute shareholders, even as it attempts to penetrate a large U.S. acne market of more than 5 million treatment-seeking patients.

Information on this page is provided for informational purposes only and is not a recommendation to buy, sell or hold any security. Investing involves risk, including possible loss of principal. Market data is delayed at least 15 minutes and is provided without warranty. Analyst ratings, price targets and company data come from third-party sources. Past performance does not guarantee future results.